Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 9/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18384682 | 0.94 | LMNA (0.43) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL29488 | 0.80 | LMNA (0.50) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL18384693 | 0.80 | TSHR (0.46) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL21414054 | 0.76 | ALDH1A1 (0.41) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL18384678 | 0.74 | TSHR (0.46) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL12700187 | 0.74 | KDM4E (0.40) | LMNAALDH1A1KDM4EMEN1POLB | |
| SCHEMBL18384647 | 0.73 | PDE4A (0.47) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL18384660 | 0.73 | PDE4A (0.47) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL22172519 | 0.72 | GAA (0.39) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL20851837 | 0.72 | KDM4E (0.32) | RECQLKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934309-B2 | Tricyclic quinone derivative | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-3127907-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | Boston Biomedical, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3127907-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | Boston Biomedical, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | LMNA 4786/4885RECQL 124/4885PDE4A 3952/4885 |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | LMNA 4786/4885RECQL 124/4885PDE4A 3952/4885 |
| US-10934309-B2 | Tricyclic quinone derivative | NQO1, NQO2, SQOR | LMNA 4822/4885RECQL 102/4885PDE4A 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.